Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
Medicine (Baltimore). 2021 Aug 13;100(32):e26892. doi: 10.1097/MD.0000000000026892.
There was no previous report on the prognostic impact of new-onset or improved anemia after discharge from acute decompensated heart failure (ADHF).We analyzed 771 patients with ADHF and who were followed in multicenters in Japan was divided into 4 groups based on the hemoglobin values at discharge and 6-month index visit: 373 patients (48.4%) with persistent anemia, 87 patients (11.3%) with new-onset anemia, 91 patients (11.8%) with improved anemia, and 220 patients (28.5%) without anemia.The primary outcome measure was a composite of all-cause death or HF hospitalization after index visit. The cumulative 6-month incidences of the primary outcome measure were 25.2% for persistent anemia, 18.5% for new onset anemia, 9.0% for improved anemia, and 9.2% for no anemia (log-rank P < .001). Compared with the no anemia group, the excess risk for the primary outcome measure remained significant in the persistent anemia group [hazard ratio (HR) 2.70, 95% confidence interval (95% CI), 1.45-5.44, P = .001] and in the new-onset anemia group (HR 2.73, 95% CI 1.19-6.25, P = .02), while it was not significant in the improved anemia group (HR 1.69, 95% CI 0.68-4.03, P = .25).Persistent and new-onset anemia at 6-month visit were associated with a subsequent higher risk for all-cause death or HF hospitalization in patients with ADHF, suggesting the importance of detecting anemia during follow-up.
尚无关于急性失代偿性心力衰竭(ADHF)出院后新发或改善的贫血对预后影响的报告。我们分析了在日本多中心接受随访的 771 例 ADHF 患者,根据出院时和 6 个月随访时的血红蛋白值将患者分为 4 组:持续性贫血患者 373 例(48.4%),新发贫血患者 87 例(11.3%),贫血改善患者 91 例(11.8%),无贫血患者 220 例(28.5%)。主要终点是随访时全因死亡或心力衰竭住院的复合终点。持续性贫血组、新发贫血组、贫血改善组和无贫血组的主要终点累积 6 个月发生率分别为 25.2%、18.5%、9.0%和 9.2%(对数秩检验 P<0.001)。与无贫血组相比,持续性贫血组(HR 2.70,95%CI 1.45-5.44,P=0.001)和新发贫血组(HR 2.73,95%CI 1.19-6.25,P=0.02)发生主要终点事件的风险仍然显著升高,而贫血改善组无显著差异(HR 1.69,95%CI 0.68-4.03,P=0.25)。ADHF 患者在 6 个月随访时持续性和新发贫血与全因死亡或心力衰竭住院的风险增加相关,提示在随访期间检测贫血的重要性。